IL6 and diabetes mellitus: The proposed mechanism involves the elevation of serum glucagon-like peptide-1 (GLP-1) levels, which subsequently reduce serum interleukin-6 (IL-6) levels and downregulate IL-6 expression in white adipose tissue, serving as an inflammatory marker in mice with diabetes [27, 29–31].